{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "INT-6",
        "affectedSection": "Synopsis; 11.3.5 Interim Analysis",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Reduction in the number of primary composite events required for the interim analysis from 540 to 405."
      },
      {
        "id": "impact_2",
        "amendmentId": "INT-6",
        "affectedSection": "Section 12 - Adverse Event Reporting",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Designation of pancreatitis and lower-extremity amputations as adverse events of special interest requiring 24-hour reporting."
      },
      {
        "id": "impact_3",
        "amendmentId": "INT-5",
        "affectedSection": "Section 4.2 - Exclusion Criteria",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added exclusion criteria for subjects at high risk of lower extremity amputation."
      },
      {
        "id": "impact_4",
        "amendmentId": "INT-4",
        "affectedSection": "Section 11.2 - Sample Size Determination",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Increased sample size from 3,700 to 4,200 subjects due to recruitment rates."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "INT-6",
        "reasonText": "Beneficial effects of canagliflozin on renal outcomes may be detected with fewer events based on internal and external data.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "INT-6",
        "reasonText": "To inform investigators of additional safety reporting requirements associated with events of pancreatitis.",
        "category": "Safety",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "INT-5",
        "reasonText": "Include new safety information and guidance regarding subject management surrounding the event of lower extremity amputations.",
        "category": "Safety",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "INT-2",
        "reasonText": "To include subjects with higher baseline HbA1c who may be at increased risk for renal and cardiovascular events.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "INT-6",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "11.3.5",
        "beforeText": "540",
        "afterText": "405",
        "summary": "Decreased the number of primary composite events required for the interim analysis."
      },
      {
        "id": "change_2",
        "amendmentId": "INT-6",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "10.2.1",
        "beforeText": "The subject requires disallowed therapy",
        "afterText": "The subject is currently using disallowed therapy",
        "summary": "Updated language to accommodate subjects already using disallowed medication."
      },
      {
        "id": "change_3",
        "amendmentId": "INT-2",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "4.2",
        "beforeText": "HbA1c level ≤10.5%",
        "afterText": "HbA1c level ≤12.0%",
        "summary": "Increased the upper limit of HbA1c for study entry."
      },
      {
        "id": "change_4",
        "amendmentId": "INT-6",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "10.2.1",
        "beforeText": "when chronic dialysis or renal transplant is required",
        "afterText": "when chronic dialysis or renal transplant is initiated",
        "summary": "Clarified the trigger for study drug discontinuation regarding renal replacement therapy."
      }
    ],
    "summary": {
      "impactCount": 4,
      "reasonCount": 4,
      "changeCount": 4
    }
  }
}